Early prediction of LVSD and timely application of recombinant human brain natriuretic peptide, levosimendan, aldosterone antagonist or sodium-glucose cotransporter type 2 inhibitors may reduce the occurrence of HF after AMI [41–44]. This evidence concerns the gene NPPB and hydrops fetalis.